Trial reportNeuro-oncology2020
Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report.
Trial report in Neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05286788 (Phase 2 Study of the MEK Inhibitor MEKTOVI®), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 2 Study of the MEK Inhibitor MEKTOVI® (Binimetinib) for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Advancing Craniopharyngioma Management: A Systematic Review of Current Targeted Therapies and Future Perspectives.International journal of molecular sciences · 2024Pooled it
- Case-based review: Craniopharyngioma treated with intracystic peginterferon.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Review
- Pharmacological Treatment for Adamantinomatous Craniopharyngioma.Current oncology reports · 2025Review
- Old Tools in a New Era: The Continued Relevance of Chemotherapy in Pediatric Neuro-Oncology.Current oncology (Toronto, Ont.) · 2025Review
- Molecular subtypes of adamantinomatous craniopharyngiomas.Neuro-oncology · 2025Review
- Craniopharyngiomas in children: the pendulum moves again for an aggressive surgery-late complications and considerations with a recent series of 26 patients treated in Lyon.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- Targeted Treatment of Pediatric Craniopharyngioma: Lesson Learnt After 20-Year Experience with Intracystic Interferon Alpha.Advances and technical standards in neurosurgery · 2025Article
- Recent advances in craniopharyngioma pathophysiology and emerging therapeutic approaches.Frontiers in endocrinology · 2025Review
- A case-based review of adult-onset craniopharyngioma.Frontiers in endocrinology · 2025Review
- Impact of stereotactic radiotherapy for craniopharyngioma: a large, academic hospital cohort.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Article
- Clinical and translational advances in primary brain tumor therapy with a focus on glioblastoma-A comprehensive review of the literature.World neurosurgery: X · 2024Review
- Single-cell and spatial sequencing identifies senescent and germinal tumor cells in adamantinomatous craniopharyngiomas.Cell & bioscience · 2024Article
- Pediatric-Like Brain Tumors in Adults.Advances and technical standards in neurosurgery · 2024Review
- Adamantinomatous craniopharyngioma: evolution in the management.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023Review
- Molecular biological features of cyst wall of adamantinomatous craniopharyngioma.Scientific reports · 2023Article
- Response assessment in pediatric craniopharyngioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) Working Group.Neuro-oncology · 2023Article
- Novel therapeutic approaches for pediatric diencephalic tumors: improving functional outcomes.Frontiers in oncology · 2023Review
- Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report.Frontiers in endocrinology · 2023Article
- Disease Control after Radiotherapy for Adult Craniopharyngioma: Clinical Outcomes from a Large Single-Institution Series.Journal of neuro-oncology · 2022Article
- Treatment of Cystic Craniopharyngiomas: An Update.Advances and technical standards in neurosurgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 13 institutions in 1 country.
Funding
Abstract
backgroundCraniopharyngiomas account for approximately 1.2-4% of all CNS tumors. They are typically treated with a combination of surgical resection and focal radiotherapy. Unfortunately, treatment can lead to permanent deleterious effects on behavior, learning, and endocrine function.
methodsThe Pediatric Brain Tumor Consortium performed a multicenter phase 2 study in children and young adults with unresectable or recurrent craniopharyngioma (PBTC-039). Between December 2013 and November 2017, nineteen patients (median age at enrollment, 13.1 y; range, 2-25 y) were enrolled in one of 2 strata: patients previously treated with surgery alone (stratum 1) or who received radiation (stratum 2).
resultsEighteen eligible patients (8 male, 10 female) were treated with weekly subcutaneous pegylated interferon alpha-2b for up to 18 courses (108 wk). Therapy was well tolerated with no grade 4 or 5 toxicities. 2 of the 7 eligible patients (28.6%) in stratum 1 had a partial response, but only one response was sustained for more than 3 months. None of the 11 stratum 2 patients had an objective radiographic response, although median progression-free survival was 19.5 months.
conclusionsPegylated interferon alpha-2b treatment, in lieu of or following radiotherapy, was well tolerated in children and young adults with recurrent craniopharyngiomas. Although objective responses were limited, progression-free survival results are encouraging, warranting further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.